Mechanisms of prostate atrophy after LHRH antagonist cetrorelix injection: An experimental study in a rat model of benign prostatic hyperplasia

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 32, Issue 3, 2012, Pages 389-395

  Yang, Dong ^a   Hou, Teng ^b   Yang, Xiong ^a   Ma, Yan ^a   Wang, Longwang ^a   Li, Bing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

Benign prostatic hyperplasia; LHRH; Transforming growth factor

Indexed keywords

CETRORELIX; DRUG DERIVATIVE; GONADORELIN; HORMONE ANTAGONIST; MYC PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ARTICLE; ATROPHY; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; MALE; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE HYPERTROPHY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ATROPHY; DISEASE MODELS, ANIMAL; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; MALE; ORGAN SIZE; PROSTATIC HYPERPLASIA; PROTO-ONCOGENE PROTEINS C-MYC; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84865609223     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-012-0067-x     Document Type: Article

References (45)

1. Rick FG, Schally AV, Block NL, et al. LHRH antagonist cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate, 2011, 71(7):736-747
2. Hoke GP, McWilliams GW. Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. Am J Med, 2008,121(8 Suppl 2):S3-S10
3. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: Age-related tissue-remodeling. Exp Gerontol, 2005,40(3):121-128 (Pubitemid 40343002)
4. Lucia MS, Lambert Jr. Growth factors in benign prostatic hyperplasia: Basic science implications. Curr Urol Rep, 2008,9(4):272-278
5. Eaton CL. Aetiology and pathogenesis of benign prostatic hyperplasia. Curr Opin Urol, 2003,13(1):7-10 (Pubitemid 36106323)
6. Culig Z, Hobisch A, Cronauer MV, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate, 1996,28(6):392-405 (Pubitemid 26187724)
7. Debruyne F, Tzvetkov M, Altarac S, et al. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology, 2010,76(4):927-933
8. Comaru-Schally AM, Brannan W, Schally AV, et al. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab, 1998,83(11):3826-3831 (Pubitemid 28513557)
9. Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol, 2008, 54(1):170-177
10. Lepor H. The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Rev Urol, 2006,8(4):183-189
11. Engel JB, Schally AV. Drug Insight: Clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab, 2007,3(2): 157-167 (Pubitemid 46146968)
12. Siejka A, Schally AV, Block NL, et al. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int, 2010,106(9):1382-1388
13. Rozsa B, Nadji M, Schally AV, et al. Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix. Prostate, 2011,71(5):445-452
14. Lee C, Sintich SM, Mathews EP, et al. Transforming growth factor-beta in benign and malignant prostate. Prostate, 1999,39(4):285-290 (Pubitemid 29244503)
15. Huang X, Lee C. Regulation of stromal proliferation, growth arrest, differentiation and apoptosis in benign prostatic hyperplasia by TGF-beta. Front Biosci, 2003,8:s 740-s749 (Pubitemid 39140194)
16. Brodin G, ten Dijke P, Funa K, et al. Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res, 1999,59(11):2731-2738 (Pubitemid 29269123)
17. Landstrom M, Eklov S, Colosetti P, et al. Estrogen induces apoptosis in a rat prostatic adenocarcinoma: Association with an increased expression of TGF-beta 1 and its type- and type- receptors. Int J Cancer, 1996, 67(4):573-579 (Pubitemid 26274116)
18. Warner BJ, Blain SW, Seoane J, et al. Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway. Mol Cell Biol, 1999,19(9):5913-5922 (Pubitemid 29399296)
19. Yagi K, Furuhashi M, Aoki H, et al. c-myc is a downstream target of the Smad pathway. J Biol Chem, 2002, 277(1):854-861 (Pubitemid 34952127)
20. Scolnik MD, Servadio C, Abramovici A. Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. J Androl, 1994,15(4):287-297 (Pubitemid 24256641)
21. Horvath JE, Toller GL, Schally AV, et al. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. Proc Natl Acad Sci USA, 2004,101(14):4996-5001 (Pubitemid 38469191)
22. Tsujimura A, Koikawa Y, Salm S, et al. Proximal location of mouse prostate epithelial stem cells: A model of prostatic homeostasis. J Cell Biol, 2002,157(7):1257-1265 (Pubitemid 34851270)
23. Tieva A, Bergh A, Damber JE. The clinical implications of the difference between castration, gonadotrophin releasing- hormone (GnRH) antagonists and agonist treatment on the morphology and expression of GnRH receptors in the rat ventral prostate. BJU Int, 2003,91(3): 227-233 (Pubitemid 36232841)
24. Kramer G, Steiner GE, Handisurya A, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate, 2002, 52(1):43-58 (Pubitemid 34553191)
25. Li X, Wang Y, Sharif-Afshar AR, et al. Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling. Differentiation, 2009,77(1): 95-102
26. Sintich SM, Lamm ML, Sensibar JA, et al. Transforming growth factor-beta1-induced proliferation of the prostate cancer cell line, TSU-Pr1: The role of platelet-derived growth factor. Endocrinology, 1999,140(8):3411-3415 (Pubitemid 30645395)
27. Xi L, Hu W, Meng L, et al. Dysregulation of the TGF-beta postreceptor signaling pathway in cell lines derived from primary or metastatic ovarian cancer. J Huazhong Univ Sci Technolog [Med Sci], 2004,24(1): 62-65 (Pubitemid 41568307)
28. Lee KY, Bae SC. TGF-beta-dependent cell growth arrest and apoptosis. J Biochem Mol Biol, 2002,35(1):47-53 (Pubitemid 35216580)
29. Nemeth JA, Sensibar JA, White RR, et al. Prostatic ductal system in rats: Tissue-specific expression and regional variation in stromal distribution of transforming growth factor-beta 1. Prostate, 1997,33(1):64-71 (Pubitemid 27381597)
30. Ma QJ, Gu XQ, Cao X, et al. Effect of beta radiation on TGF-beta1 and bFGF expression in hyperplastic prostatic tissues. Asian J Androl, 2005, 7(1):49-54 (Pubitemid 40361066)
31. Klingler HC, Bretland AJ, Reid SV, et al. Regulation of prostatic stromal cell growth and function by transforming growth factor beta (TGFbeta). Prostate, 1999,41(2): 110-120 (Pubitemid 29446965)
32. Hsing AY, Kadomatsu K, Bonham MJ, et al. Regulation of apoptosis induced by transforming growth factor-beta1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res, 1996,56(22):5146-5149 (Pubitemid 26383028)
33. Pelengaris S, Khan M. The many faces of c-MYC. Arch Biochem Biophys, 2003,416(2):129-136 (Pubitemid 36945150)
34. Eilers M. Control of cell proliferation by Myc family genes. Mol Cells, 1999,9(1):1-6 (Pubitemid 129620069)
35. Amati B. Integrating Myc and TGF-beta signalling in cell-cycle control. Nat Cell Biol, 2001,3(5):E112-113
36. Gartel AL, Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res, 2003,283(1):17-21 (Pubitemid 36259892)
37. Pello OM, De Pizzol M, Mirolo M, et al. Role of c-MYC in alternative activation of human macrophages and tumor- associated macrophage biology. Blood, 2012,119(2): 411-421
38. Kawakami Y, Kubota N, Ekuni N, et al. Tumor- suppressive lipoxygenases inhibit the expression of c-myc mRNA coding region determinant-binding protein/ insulin-like growth factor II mRNA-binding protein 1 in human prostate carcinoma PC-3 cells. Biosci Biotechnol Biochem, 2009,73(8):1811-1817
39. Wang H, Mannava S, Grachtchouk V, et al. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene, 2008,27(13): 1905-1915 (Pubitemid 351430817)
40. Dai W, Chen H, Yu R, et al. Effects of cadmium on telomerase activity, expressions of TERT, c-myc and P53, and apoptosis of rat hepatocytes. J Huazhong Univ Sci Technolog [Med Sci], 2010,30(6):709-713
41. Herzinger T, Wolf DA, Eick D, et al. The pRb-related protein p130 is a possible effector of transforming growth factor beta 1 induced cell cycle arrest in keratinocytes. Oncogene, 1995,10(11):2079-2084
42. Alexandrow MG, Kawabata M, Aakre M, et al. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. Proc Natl Acad Sci USA, 1995,92(8):3239-3243
43. Claassen GF, Hann SR. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta-induced cell-cycle arrest. Proc Natl Acad Sci USA, 2000,97(17):9498-9503 (Pubitemid 30650804)
44. Kidder BL, Yang J, Palmer S. Stat3 and c-Myc genome- wide promoter occupancy in embryonic stem cells. PLoS One, 2008,3(12):e3932
45. Dong J, Sutor S, Jiang G, et al. c-Myc regulates self-renewal in bronchoalveolar stem cells. PLoS One, 2011,6(8):e23707